Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared ...

Novavax Inc. shares climbed 2% on Wednesday and extended gains in after-hours trading, as retail investors maintained a ...

The Lowe's Foundation today announced nearly $9 million in Gable Grants to strengthen 15 nonprofits on the front lines of a growing skilled trades workforce movement. From Alaska to Mississippi, each ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Novavax reported a Q4 2024 EPS of -$0.51, surpassing expectations. Revenue for the quarter fell to $88.3 million, missing forecasts and down from $291 million in Q4 2023. The company reduced R&D ...